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Abstract
Background: Moderately elevated blood levels of homocysteine are weakly correlated with coronary heart disease (CHD)
risk, but causality remains uncertain. When folate levels are low, the TT genotype of the common C677T polymorphism
(rs1801133) of the methylene tetrahydrofolate reductase gene (MTHFR) appreciably increases homocysteine levels, so
‘‘Mendelian randomization’’ studies using this variant as an instrumental variable could help test causality.
Methods and Findings: Nineteen unpublished datasets were obtained (total 48,175 CHD cases and 67,961 controls) in
which multiple genetic variants had been measured, including MTHFR C677T. These datasets did not include measurements
of blood homocysteine, but homocysteine levels would be expected to be about 20% higher with TT than with CC
genotype in the populations studied. In meta-analyses of these unpublished datasets, the case-control CHD odds ratio (OR)
and 95% CI comparing TT versus CC homozygotes was 1.02 (0.98–1.07; p=0.28) overall, and 1.01 (0.95–1.07) in
unsupplemented low-folate populations. By contrast, in a slightly updated meta-analysis of the 86 published studies (28,617
CHD cases and 41,857 controls), the OR was 1.15 (1.09–1.21), significantly discrepant (p=0.001) with the OR in the
unpublished datasets. Within the meta-analysis of published studies, the OR was 1.12 (1.04–1.21) in the 14 larger studies
(those with variance of log OR,0.05; total 13,119 cases) and 1.18 (1.09–1.28) in the 72 smaller ones (total 15,498 cases).
Conclusions: The CI for the overall result from large unpublished datasets shows lifelong moderate homocysteine elevation
has little or no effect on CHD. The discrepant overall result from previously published studies reflects publication bias or
methodological problems.
Please see later in the article for the Editors’ Summary.
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Rare genetic defects that cause extremely high plasma
homocysteine levels also cause coronary heart disease (CHD) [1–
3]. It was therefore hypothesised that, even within the normal
range of plasma homocysteine concentrations, higher levels might
appreciably increase CHD risk [3]. Retrospective studies originally
suggested a strong relationship, but subsequent prospective
observational studies suggested weaker associations [3,4]. A
meta-analysis of prospective studies found that, after adjusting
for known risk factors, 25% lower usual homocysteine level
(achievable in many populations by fortification of cereals with
folic acid) was associated with only about 11% (95% CI 4%–17%,
p,0.001) lower CHD risk [4]. Although significant, the weak
association represented by the lower confidence limit could be
largely or wholly noncausal (as, for example, homocysteine might
be associated with renal failure or other vascular risk factors, or
might reflect preexisting atherosclerosis).
A meta-analysis of the randomized trials of folic acid, involving
37,485 individuals, reported that an average 25% reduction in
homocysteine levels throughout a median follow-up of 5 y had no
significant effect on major vascular events [5]. As the duration of
treatment was only a few years, it has been suggested that more
prolonged treatment might be protective against the onset of CHD
[6]. Hence, reliable studies are needed of genetic variants that
affect homocysteine levels throughout life.
The enzyme methylene tetrahydrofolate reductase, encoded by
the MTHFR gene, uses folate to metabolise and thereby remove
homocysteine [7]. The MTHFR C677T polymorphism
(rs1801133) is common (T-allele frequency 15%–45% in many
populations) and reduces enzyme efficiency. In many populations
without folic acid fortification, individuals with TT genotype have
about 20% higher homocysteine than those with the more
common CC genotype [8,9]. Individuals are, in effect, randomly
allocated at conception to MTHFR genotype and, hence, to higher
or lower lifelong homocysteine levels [9]. If the associations seen in
prospective studies were largely causal, the 20% higher usual
homocysteine in TT homozygotes would imply about 8% (95% CI
3%–13%) higher CHD risk.
Such Mendelian randomized studies of the associations of
MTHFR genotype with CHD assess the effects of lifelong
homocysteine differences and should not be materially affected
by confounding if each study is of a reasonably homogeneous
population (or if any population admixture can be adequately
allowed for) [9]. Because the expected effect on risk is small,
however, reliable assessment of it requires extremely large
numbers of cases and strict avoidance of any potential sources of
moderate bias, including publication bias. Previous meta-analyses
just of the published studies [6,10–12] have found, in aggregate, a
highly significant but only moderately positive association of
MTHFR genotype with CHD risk (odds ratio [OR] for TT versus
CC genotype of 1.16 in the most recent report [6]), but opinions
differ as to whether publication bias could explain away this
aggregate result [6,10–12]. As genotyping has become less
expensive, large datasets have started to emerge from genome-
wide association (GWA) and gene-chip studies in which MTHFR
C677T was analyzed largely incidentally as one of many
thousands, or even hundreds of thousands, of polymorphisms
included on standard genotyping platforms. In none of these
studies had the MTHFR OR been published. The MTHFR
variant, together with multiple other polymorphisms, had also
been genotyped in some large previously unpublished case-control
studies.
We report meta-analyses of the association of the MTHFR
C677T polymorphism with CHD risk in these unpublished
datasets and contrast them with meta-analyses of the published
studies of this polymorphism and an updated meta-analysis of the
CHD results in the randomized trials of B-vitamins for
homocysteine reduction. In some populations, introduction of
folic acid fortification around the mid-1990s changed mean
plasma folate levels appreciably [13]. Previous meta-analyses did
not take account of secular changes in folate [6,14] when
considering associations of MTHFR genotype with CHD [6,10–
12]. We subdivide our findings by the approximate effects of the
C677T polymorphism on homocysteine levels expected in the
different populations studied.
Methods
Unpublished Studies of MTHFR and CHD
Previously unpublished CHD case-control results were sought
from large-scale genotyping datasets: from the two large
collaborative consortia, C4D [15] and CARDIOGRAM [16],
convened to conduct meta-analyses with maximum power to
detect novel susceptibility variants for CHD (all members with
data on rs1801133 collaborated); and from other affiliated
studies, including the ISIS case-control study [17], the INTER-
HEART study [18], and from the investigators of large-scale
genotyping studies in Japan (all of whom collaborated). The
genotyping panels ranged in panel size from 67 polymorphisms to
hundreds of thousands of polymorphisms, and results were
adjusted internally where investigators were able to do so for
population admixture and familial clustering. In none of these
studies was the MTHFR polymorphism of primary interest, and
their MTHFR CHD ORs had, when we requested data, not yet
been reported, so these are referred to as unpublished datasets.
Some of these studies had, in publications on their positive
findings, implied that any association with MTHFR was
nonsignificant (at some significance level). CHD was defined as
death from CHD, myocardial infarction (by WHO MONICA
criteria [19]), or angiographic stenosis (involving at least 50% of a
major coronary artery). Almost all CHD cases (when bled) had
nonfatal myocardial infarction. No unpublished studies (and few
published ones) were of angiographic CHD only. We identified a
total of 48,175 CHD cases and 67,961 controls in these
unpublished datasets (Table S1 in Text S1).
Published Studies of MTHFR and CHD
Previous meta-analyses of published studies [6,9,10–
12,14,20] were updated by searching the electronic literature
(PubMed, Current Contents, and HuGENet) seeking relevant
studies published before 2010 using search terms ‘‘MTHFR’’
and ‘‘coronary heart disease’’ or ‘‘coronary stenosis’’ or
‘‘myocardial infarction,’’ or by hand-searching reference lists
of identified studies, review articles, and previous meta-
analyses, and by contacting investigators. Studies were included
if they had been published as articles or letters in peer-reviewed
journals, had a case-control design or a nested case-control
design within a prospective study, and reported their results by
genotype. If two reports of the same study were found, only the
one based on the larger dataset was used. For published case-
control studies, individual participant datasets were sought;
where unavailable, tabular data sufficed (checked if possible
with investigators). We identified a total of 28,617 cases and
41,857 controls in 86 published case-control studies (Figure S1;
Table S2 in Text S1).
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Of the 86 published case-control studies, only 37 yielded data
on normal homocysteine levels (in a total of 14,774 controls). None
of the unpublished datasets yielded such data, as the investigations
were not particularly concerned with homocysteine. Additional
eligible studies were identified by searching the electronic
literature (PubMed, Current Contents, and HuGENet) using the
search terms ‘‘MTHFR’’ and ‘‘homocysteine’’ or ‘‘total homocys-
teine’’ for relevant reports published before 2010, by hand
searching reference lists of original studies and review articles
(including meta-analyses) on this topic seeking data on the
MTHFR genotypes and plasma homocysteine levels in disease-
free individuals. The search criteria identified 53,595 other
disease-free individuals with homocysteine data in 33 other
MTHFR publications, yielding a total of 70 published studies of
the biochemical effects of MTHFR genotype on homocysteine
(Figure S1; Table S3 in Text S1).
Categorization of MTHFR Studies by Probable Folate
Status
Folate status was generally unknown in the MTHFR studies. As
a surrogate for it, these MTHFR studies were classified by study
place and time into five probable folate status categories, on the
basis of when national legislation permitting or requiring folic acid
fortification came into effect (Appendix S1 in Text S1). Population
surveys of folate status published before the end of 2009 of healthy
individuals, including controls from case-control studies or
participants in randomized trials in healthy volunteers were
identified from previous meta-analyses [4,11,21] and by searching
the electronic literature using the search terms ‘‘homocysteine,’’
‘‘total homocysteine,’’ ‘‘folic acid,’’ ‘‘folate,’’ ‘‘B-vitamins,’’ ‘‘folic
acid fortification,’’ and ‘‘population or nutrition surveys.’’ The
search criteria identified 81 population-based surveys that
reported mean serum folate levels in general population samples
of .100 people (Figure S2; Table S4 in Text S1). Mean folate
levels were estimated for each of these five categories on the basis
of secular and geographic trends in folic acid fortification policies
(Appendix S1 in Text S1).
Randomized Folate Trials
Finally, we updated a previous meta-analysis [5] of seven large-
scale placebo-controlled trials assessing the effects on cardiovas-
cular disease of lowering homocysteine with B-vitamins by adding
three trials [22–24] that reported their results after publication of
the meta-analysis (Table S5 in Text S1). The additional trials were
identified by searching the electronic literature using search terms
‘‘cardiovascular disease,’’ ‘‘coronary heart disease,’’ ‘‘coronary
stenosis,’’ ‘‘myocardial infarction’’ and ‘‘randomized controlled
trial,’’ ‘‘clinical trial,’’ and ‘‘folic acid’’ or ‘‘B-vitamins.’’ As in the
original meta-analysis [5], additional randomized trials were
eligible if (i) they involved a double-blind randomized comparison
of B-vitamin supplements containing folic acid versus placebo for
the prevention of vascular disease; (ii) the relevant treatment arms
differed only with respect to the homocysteine-lowering interven-
tion; and (iii) the trial involved $1,000 participants with treatment
duration of $1y .
Statistical Methods
Mean folate levels and mean log homocysteine by genotype
were estimated from individual participant data where available,
or from published reports. In calculating these means we sought
to give all individuals similar weight, so large studies contribute
proportionally more than small ones. (Random effects models
were not used, as they can give undue weight to individuals in
smaller studies [25].) The homocysteine difference between TT
and CC genotypes was estimated from linear regression
(stratified by study) of log homocysteine on genotype in
heterozygotes [26,27]. The CHD OR for TT versus CC
genotype (OR) was estimated by logistic regression, stratified
by study; this yields an approximately inverse-variance-weighted
average of the log OR in each study. In the PROCARDIS study,
which included both related and unrelated cases and controls,
allowance for familial clustering was made, which slightly
increased the variance estimate [15]. In the LOLIPOP and
PROMIS studies of South Asians also, the CHD OR for TT
versus CC genotypes was estimated after correction for
population admixture (to avoid false positive association due to
population stratification) using adjustment for principal compo-
nents involving the results of random genetic markers within that
study [15], which was not possible in the published studies.
Details of the methods used to estimate nonpublication bias are
shown in Appendix S2 in Text S1. Heterogeneity was assessed
using chi-squared tests [28], also citing I
2=100%(12[degrees of
freedom]/[chi-squared test statistic]) [29]. CIs are 95%, except
where specified as 99% to allow for multiple comparisons.
Analyses used SAS version 9.1.
Results
Figure 1 plots mean folate levels by calendar year in 81
population surveys (total 200,103 participants), categorising the
surveys by study place (Asia, Europe or North America and
Australasia [US & ANZ]) and time (before or after national folate
supplementation began). Asian surveys were all in unsupplemen-
ted populations, so Figure 1 defines only five probable folate status
categories. Table 1 gives the mean folate levels in each category.
Although assay methods may have varied, there appeared to be
similarly low folate levels in the Asian and unsupplemented
European populations (11.0 and 11.9 nmol/l), intermediate folate
levels in the supplemented European and unsupplemented US and
ANZ populations (18.2 and 20.8 nmol/l), and high folate levels in
supplemented US and ANZ populations (33.3 nmol/l). Thus,
there are only two low-folate unsupplemented categories.
Homocysteine differences by MTHFR genotype are also given
in Table 1, based on 70 biochemical studies of MTHFR genotype
and homocysteine in the general population (total 68,369
participants, mostly Caucasian or East Asian). These analyses of
within-study percentage differences in homocysteine levels be-
tween TT and CC genotypes (Figure S3) should be little affected
by any variation in homocysteine assay methods. The TT versus
CC homocysteine difference appears to have been only moder-
ately affected by folate supplementation, but was appreciably
greater in Asia and Europe than in the US & ANZ (although the
TT versus CC homocysteine difference in US & ANZ after folate
supplementation had a wide CI and is not reliably known).
Differences in homocysteine between the CT and CC genotypes
were only about a quarter as great as those between the
homozygous TT and CC genotypes (Figure S3). Tables S3 and
S4 in Text S1 give separately each survey of folate levels and each
study of MTHFR genotype and homocysteine, and Tables S1, S2
in Text S1 give separately each case-control study result. Among
the controls there was substantial variation in genotype frequencies
(ratio of TT to CC 0.03–0.04 in South Asians, 0.2–0.3 in northern
Europe, 0.4 or more in Japan, and 0.7 in Italy), illustrating the
potential for bias from population substructure.
Our case-control analyses of MTHFR genotype and CHD risk
compare TT versus CC homozygotes, as this is the comparison
Meta-analysis of MTHFR Case-Control Studies
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CHD risk in the unpublished datasets are given in Figure 2,
subdivided by the number of variants examined (i.e., genotyping
panel size). Overall, there would have been about a 20% excess
homocysteine associated with the TT versus the CC genotype, but
the excess CHD risk associated with the TT versus the CC
genotype was only 2%, was not significant (OR=1.02, 95% CI
0.98–1.07, p=0.28), and was similar in the datasets with larger
and small genotyping panel sizes. Any null bias from nonpublica-
tion would have biased the expected log OR in the aggregate of all
unpublished studies downwards by only about 0.001 (0.003 in the
small-panel studies and 0.0002 in the large-panel studies:
Appendix S2 in Text S1), thereby multiplying the overall OR by
0.999, which is negligible.
Figure 3 categorizes these results by the probable folate status of
the populations studied. Half the evidence was from low-folate
unsupplemented populations in Asia or Europe. But, even if
attention is restricted to these populations (where the excess of
homocysteine associated with the TT versus CC genotype would
have been somewhat greater than elsewhere), there was still no
evidence that the TT genotype was associated with any excess risk
of CHD (OR=1.01: 1.03 in low-folate Asia, 0.99 in low-folate
Europe; Figure 3). As the homocysteine difference between CT
and CC genotypes is only about a quarter of that between TT and
CC genotypes, inclusion of the CT results does not materially alter
these findings (Figure S4). Thus, the aggregated results from the 19
unpublished datasets suggested little or no hazard, even in
unsupplemented low-folate populations.
Figure 1. Mean serum folate concentrations in 81 population surveys, by calendar year and region. White squares, no folate
supplementation; black squares, after folate supplementation; broken vertical line, 1995–1996, when folate supplementation began in the United
States, Canada, Australia, New Zealand (US & ANZ), and some but not all European countries. No Asian surveys were in supplemented populations.
doi:10.1371/journal.pmed.1001177.g001
Table 1. Relevance in population surveys of study place and time to (i) the mean general population serum folate level, and (ii) the
excess plasma homocysteine level in the TT versus CC MTHFR C677T genotype.
Region, and Whether after
Folate Supplementation Surveys of Folate Levels
Studies of MTHFR C677T Genotype
and Plasma Homocysteine
Folate
Surveys n people
Mean (SE)
Serum Folate
Concentration,
nmol/l
a
Homocysteine
MTHFR Studies n People
Percent Higher
Homocysteine,
TT Versus CC
(and 99% CI)
b
Asia
c no supplementation 7 4,841 11.0 (0.014) 15 6,553 25 (21–30)
Europe, presupplementation 21 31,767 11.9 (0.006) 14 24,199 21 (19–24)
Europe, post-supplementation 30 13,504 18.2 (0.009) 25 8,702 18 (15–22)
US & ANZ, presupplementation 13 57,104 20.8 (0.004) 8 26,853 13 (11–15)
US & ANZ, post-supplementation 10 92,887 33.3 (0.003) 8 2,062 7 (2–13)
All regions and time periods 81 200,103 24.8 (0.002) 70 68,369 18 (17–19)
aMean folate levels average all who were surveyed; SE denotes the standard error due only to within-survey variation. Between-survey variation in folate levels is
illustrated in Figure 1.
bFrom inverse-variance-weighted averages of within-study differences in log homocysteine; Figure S1, Table S2 in Text S1.
cMainly of Japanese, Chinese, or Korean populations; none of South Asians.
doi:10.1371/journal.pmed.1001177.t001
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published studies (total 28,617 cases and 41,857 controls: Figure 4;
Figure S5) suggested a 15% excess risk of CHD (OR 1.15, 95% CI
1.09–1.21), which is significantly discrepant (p=0.001) with the
results from the unpublished datasets (Figure 2). Larger studies
may be less prone than smaller ones to selective publication based
on their findings and may also be less prone to other, less clearly
recognizable, methodological problems (and, publication bias may
involve not only random but also any systematic errors due to
preferential publication of positive results) [30]. In Figure S5, the
CHD ORs in each of the 86 published studies are therefore
ordered by study size (as defined by the variance of the log OR).
Figure 4 indicates that, although the 72 smaller published studies
contributed most to the suggestion of increased risk (OR=1.18),
the 14 larger published studies, which typically had .250 cases
and .250 controls, also contributed to some extent (OR=1.12).
Figure 2. Homozygote CHD OR (TT versus CC MTHFR C677T genotype) in 19 unpublished datasets, yielding 24 parts that are
classified by genotyping panel size. For these datasets, being unpublished introduces a negligible bias (less than 0.3% for each OR and about
0.1% for the overall OR: eAppendix 1). Black squares indicate OR (with areas inversely proportional to the variance of log OR), and horizontal lines
indicate 99% CIs. The subtotals and their 99% CIs are indicated by black diamonds. The overall OR and its 95% CI is indicated by a white diamond. The
weight (defined as the inverse of the variance of the maximum likelihood estimate of the log OR) and the product of the weight times OR indicates
how much each study has contributed to the subtotals and totals. Because the weights and products are approximately additive, they can be used to
estimate the effects of ignoring particular studies, or of grouping studies in different ways.
doi:10.1371/journal.pmed.1001177.g002
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significantly increased risk. None of the others did, including those
from low-folate Europe, where TT versus CC homocysteine
differences were probably similar to those in Japan (Figure S3).
The large published and unpublished Japanese studies are
described separately in Table S6 in Text S1; in these, there
appeared to be substantial heterogeneity in the TT and CC
genotype frequencies (the odds, TT/CC, varied from 0.23 to 0.68
in controls), which makes it difficult to interpret the findings. (All
these studies were located in mainland Japan, where there is little
ethnic heterogeneity, so no large differences in genotype frequency
would be expected [31].) The large published studies in all other
populations, like the unpublished datasets, indicated no material
effect between homozygote genotype and CHD risk.
Overall, almost half of the cases in the published CHD studies
also had data on homocysteine, but those in the only two large
studies with significantly increased risk did not. Hence, when
analyses were restricted to the subset with homocysteine no
significant association between TT versus CC genotype and CHD
risk remained (unpublished data).
For the ten large trials of B-vitamins for homocysteine reduction
(Table S5 in Text S1), Figure 5 shows that folate supplementation
(which reduces normal homocysteine levels by about 25%) had
little or no effect on the 5-y incidence of CHD incidence (rate
ratio, folate versus placebo, 1.02, 95% CI 0.96–1.08).
Discussion
The present meta-analyses of unpublished datasets involving
48,175 cases and 67,961 controls finds no evidence of an increased
risk of CHD in TT versus CC homozygotes for the MTHFR
C677T polymorphism, either in all such datasets or in those from
Figure 3. Homozygote CHD OR (TT versus CC MTHFR C677T genotype) in each probable folate status category, from meta-analyses
of 19 unpublished datasets (all large). Average homocysteine difference (in the non-CHD general population) for all areas and periods is
weighted in proportion to the numbers of TT CHD cases in all 19 unpublished datasets. Nonpublication involves negligible bias: Appendix S2 in Text
S1.
doi:10.1371/journal.pmed.1001177.g003
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materially affected by publication bias and is significantly
discrepant with the moderately positive association found in our
meta-analysis of 86 published studies of this question, or,
equivalently, in other recent meta-analyses of published studies
[6,10–12].
Although publication bias (involving not only random errors but
also any systematic errors in particular studies) may well have
appreciably affected the meta-analyses of published studies,
nonpublication bias (i.e., failure to publish null results) should
have had a negligible effect on the present meta-analyses of
unpublished studies. For ORs of the magnitude that may be
plausible for MTHFR (i.e., about 1.08), the probability of a result
from a large SNP panel study reaching statistical significance after
allowance for multiple testing can be shown to be negligible (i.e.,
biasing the overall log OR by only about 0.001; Appendix S2 in
Text S1). In these datasets, the TT versus CC comparison involves
a nonsignificant excess CHD risk of only about 2% in all
populations and 1% in low-folate unsupplemented populations
(both with upper confidence limit 7%). Consistent with the null
results of the folate trials, the results of the present meta-analyses of
unpublished MTHFR studies provide no evidence for an
association of life-long moderate elevations in homocysteine levels
with CHD risk and support the suggestion [12] that the
associations observed in meta-analyses of previously published
MTHFR studies may be an artefact of publication bias.
The discrepancy between the overall results in the unpublished
and the published datasets is too extreme to be plausibly dismissed
as a chance finding (as is the discrepancy between the published
results in low-folate Europe and Japan, which refutes the
suggestion that differences in folate supplementation could explain
the differences between Japanese and other published studies).
Some studies, particularly if small, might have been prioritised for
publication by investigators, referees, or editors according to the
positivity of their results [30], and some may have been liable to
other methodological problems that bias the average of all results.
To avoid such biases, we chiefly emphasise the new results from
the previously unpublished datasets. These show little or no
hazard in Japan or elsewhere from moderate lifelong elevation of
normal homocysteine levels.
The magnitude of the effect of publication bias is substantial
and in addition to distorting the association of MTHFR with
CHD in published studies, publication bias may also help explain
the discrepant findings recently reported for MTHFR and stroke
[32].
Genetic epidemiology of the effects of common polymorphisms
on common diseases is increasingly dominated by consortia of
GWA studies with tens of thousands of cases and large panels of
tens or hundreds of thousands of polymorphisms [15,16]. Thus,
GWA (or other large panel genotyping) studies offer the possibility
of avoiding unduly data-dependent emphasis on particular studies
or on particular genetic loci and of making sophisticated allowance
for population admixture. (Such allowance was not possible in the
published studies and was available to us from only some of the
unpublished datasets [15].) Although there is little evidence of
significant population admixture in mainland Japan [31], the
Figure 4. Homozygote CHD OR (TT versus CC MTHFR C677T genotype) in each probable folate status category, from meta-analyses
of 86 published studies, 14 large (i.e., variance of log OR less than 0.05) and 72 smaller studies. Black squares indicate OR (with areas
inversely proportional to the variance of log OR in each subdivision), and horizontal lines indicate 99% CIs. The overall OR and its 95% CI are indicated
by a black diamond. Average homocysteine difference (in the non-CHD general population) for all areas and periods is weighted in proportion to the
numbers of TT CHD cases in all 86 studies.
doi:10.1371/journal.pmed.1001177.g004
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Japanese case-control studies (0.33–0.45, Table S6 in Text S1),
perhaps because variation in genotyping methods can affect
MTHFR C677T genotype calls. As these small differences in T-
allele frequency correspond to substantial differences in the TT/
CC odds (Table S5 in Text S1), they reinforce the potential
importance of cases and controls being blindly genotyped (assayed,
called, and quality-control filtered) together, particularly for a
polymorphism such as MTHFR C677T that varies in frequency
between populations and does not have a substantial effect on risk.
The Mendelian randomization approach to assessing the effects
of a particular biochemical factor such as homocysteine assumes
no relevant pleiotropic effects of the genetic variant on other
factors [33,34] (whereas, for example, the TT genotype does also
slightly affect folate levels) [35]. Large randomized trials of folate
supplementation also provide an independent test of the causal
relevance of homocysteine (assuming no material effects of folate
on CHD except via homocysteine). A meta-analysis of 10 trials
involving 50,378 participants had little or no effect on the 5-y
incidence of CHD (rate ratio, folate versus placebo, 1.02, 95% CI
0.96–1.08). The null result from the folic acid trials is now directly
reinforced by this Mendelian randomization meta-analysis of
unpublished genetic epidemiology datasets, which is not materially
affected by publication bias, involves large numbers of relevant
outcomes, and shows no evidence that even a lifelong 20%
difference in plasma homocysteine (within the normal range)
meaningfully effects CHD risk.
Supporting Information
Figure S1 Screening and selection of articles for
MTHFR and CHD risk and MTHFR and homocysteine
levels.
(TIF)
Figure S2 Screening and selection of population surveys
of folate status.
(TIF)
Figure S3 Percent higher homocysteine by MTHFR
C677T genotype in 70 biochemical studies of non-CHD
populations. Subtotal results are from inverse-variance-weight-
ed averages of within-study differences in log homocysteine, so the
Figure 5. Effects of folic acid on major coronary events (nonfatal myocardial infarction or coronary death) in a meta-analysis of the
published results of all large randomized trials of homocysteine reduction. Data for the VITATOPS trial are for myocardial infarction only.
Data for FAVORIT are for all cardiovascular disease outcomes. Symbols and conventions as in Figure 2.
doi:10.1371/journal.pmed.1001177.g005
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variation; other CIs are 99% CIs.
(TIF)
Figure S4 CHD OR (OR, TT versus CC MTHFR C677T
genotype) from CC/CT/TT results in 19 unpublished
datasets, yielding 24 parts that are classified by
probable folate status category: maximum likelihood
estimate, assuming that the underlying log OR for CT/
CC is 0.25 times that for TT/CC. Black squares indicate OR,
and horizontal lines indicate 99% CIs. The subtotals and their
99% CIs are indicated by black diamonds. The overall OR and its
95% CI is indicated by a white diamond. The weight (defined as
the inverse of the variance of the maximum likelihood estimate of
the log OR) and the product of the weight times OR indicates how
much each study has contributed to the subtotals and totals.
(TIF)
Figure S5 CHD OR for MTHFR TT versus CC genotype
in 86 published studies, from Table S4, classified by
probable folate status category and sorted by effective
study size (i.e., variance of log OR, for which the cutoff
0.05 is indicated by dashed lines). Weight is the inverse of
the variance of the maximum likelihood estimate of the log OR.
Additivity of the weights is therefore only approximate. NB,
presupplementation Europe subtotal allows for the common
control group in Frederiksen-Prospective (P) and Frederiksen-
Case-Control (CC). 95% CIs for total; other CIs are 99%.
(TIF)
Text S1 Webmaterial for homocysteine and coronary
heart disease: meta-analysis of MTHFR case-control
studies, avoiding publication bias.
(PDF)
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Background. Coronary heart disease (CHD) is the leading
cause of death among adults in developed countries. With
age, fatty deposits (atherosclerotic plaques) coat the walls of
the coronary arteries, the blood vessels that supply the heart
with oxygen and nutrients. The resultant restriction of the
heart’s blood supply causes shortness of breath, angina
(chest pains that are usually relieved by rest), and sometimes
fatal heart attacks. Many established risk factors for CHD,
including smoking, physical inactivity, being overweight, and
eating a fat-rich diet, can be modified by lifestyle changes.
Another possible modifiable risk factor for CHD is a high
blood level of the amino acid homocysteine. Methylene
tetrahydofolate reductase, which is encoded by the MTHFR
gene, uses folate to break down and remove homocysteine
so fortification of cereals with folate can reduce population
homocysteine blood levels. Pooled results from prospective
observational studies that have looked for an association
between homocysteine levels and later development of CHD
suggest that the reduction in homocysteine levels that can
be achieved by folate supplementation is associated with an
11% lower CHD risk.
Why Was This Study Done? Prospective observational
studies cannot prove that high homocysteine levels cause
CHD because of confounding, the potential presence of
other unknown shared characteristics that really cause CHD.
However, an approach called ‘‘Mendelian randomization’’
can test whether high blood homocysteine causes CHD. A
common genetic variant of the MTHFR gene—the C677T
polymorphism—reduces MTHFR efficiency so TT
homozygotes (individuals in whom both copies of the
MTHFR gene have the nucleotide thymine at position 677;
the human genome contains two copies of most genes)
have 25% higher blood homocysteine levels than CC
homozygotes. In meta-analyses (statistical pooling of the
results of several studies) of published Mendelian
randomized studies, TT homozygotes have a higher CHD
risk than CC homozygotes. Because gene variants are
inherited randomly, they are not subject to confounding,
so this result suggests that high blood homocysteine causes
CHD. But what if only Mendelian randomization studies that
found an association have been published? Such publication
bias would affect this aggregate result. Here, the researchers
investigate the association of the MTHFR C677T
polymorphism with CHD in unpublished datasets that have
analyzed this polymorphism incidentally during other
genetic studies.
What Did the Researchers Do and Find? The researchers
obtained 19 unpublished datasets that contained data on
the MTHFR C677T polymorphism in thousands of people
with and without CHD. Meta-analysis of these datasets
indicates that the excess CHD risk in TT homozygotes
compared to CC homozygotes was 2% (much lower than
predicted from the prospective observational studies), a
nonsignificant difference (that is, it could have occurred by
chance). When the probable folate status of the study
populations (based on when national folic acid fortification
legislation came into effect) was taken into account, there
was still no evidence that TT homozygotes had an excess
CHD risk. By contrast, in an updated meta-analysis of 86
published studies of the association of the polymorphism
with CHD, the excess CHD risk in TT homozygotes compared
to CC homozygotes was 15%. Finally, in a meta-analysis of
randomized trials on the use of vitamin B supplements for
homocysteine reduction, folate supplementation had no
significant effect on the 5-year incidence of CHD.
What Do These Findings Mean? These analyses of
unpublished datasets are consistent with lifelong moderate
elevation of homocysteine levels having no significant effect
on CHD risk. In other words, these findings indicate that
circulating homocysteine levels within the normal range are
not causally related to CHD risk. The meta-analysis of the
randomized trials of folate supplementation also supports
this conclusion. So why is there a discrepancy between these
findings and those of meta-analyses of published Mendelian
randomization studies? The discrepancy is too large to be
dismissed as a chance finding, suggest the researchers, but
could be the result of publication bias—some studies might
have been prioritized for publication because of the positive
nature of their results whereas the unpublished datasets
used in this study would not have been affected by any
failure to publish null results. Overall, these findings reveal a
serious example of publication bias and argue against the
use of folate supplements as a means of reducing CHD risk.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001177.
N The American Heart Association provides information
about CHD and tips on keeping the heart healthy; it also
provides information on homocysteine, folic acid, and
CHD, general information on supplements and heart
health, and personal stories about CHD
N The UK National Health Service Choices website provides
information about CHD, including personal stories about
CHD
N Information is available from the British Heart Foundation
on heart disease and keeping the heart healthy
N The US National Heart Lung and Blood Institute also
provides information on CHD (in English and Spanish)
N MedlinePlus provides links to many other sources of
information on CHD (in English and Spanish)
N Wikipedia has a page on Mendelian randomization (note:
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
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